September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
NeoADAURA Trial Launches With Plans to Assess Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC
February 18th 2021n patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations, neoadjuvant osimertinib will be administered as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone in the NeoADAURA trial
Read More
FDA Grants Sotorasib a Priority Review for KRAS G12C+ Advanced NSCLC
February 17th 2021The FDA accepted a new drug application for sotorasib and granted it a priority review for the treatment of patients with KRAS G12C–mutant locally advanced or metastatic non–small cell lung cancer following at least 1 prior systemic treatment.
Read More
PD-L1 Status Affects Physician’s Choice of Treatment in Lung Cancer
February 13th 2021For the treatment of patients with lung cancer and low PD-L1 expression, immunotherapy-based combinations have been shown effective through clinical trial research. Stephen Liu, MD, reviewed the studies during a Targeted Oncology Case-Based Peer Perspectives virtual event.
Read More
FDA Approves Trilaciclib to Reduce Chemotherapy-Induced Bone Marrow Suppression for ES-SCLC
February 12th 2021The FDA has approved trilaciclib (Cosela) as a first-in-class agent to help reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving chemotherapy for extensive-stage small cell lung cancer.
Read More
Immunotherapy Combo Use Supported in Mesothelioma
February 1st 2021Patient-reported outcomes outcomes from the Check-Mate 743 trial demonstrated improved symptom burden and maintained overall health status with the use of nivolumab/ipilimumab over chemotherapy, in patients with unresectable malignant pleural mesothelioma.
Read More
Repotrectinib Demonstrates Early Clinical Activity in ROS1+ Metastatic NSCLC
January 31st 2021Treatment with the next-generation ROS1 and TRK tyrosine kinase inhibitor repotrectinib is sustaining good objective responses and is tolerable in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated preliminary results from the phase 2 expansion 1 cohort of the ongoing phase 1/2 TRIDENT-1 clinical trial.
Read More
Maintenance Therapy With Atezolizumab Triplet Improves Survival in ES-SCLC
January 31st 2021The combination of atezolizuma plus carboplatin and etoposide demonstrated improvement in overall survival and progression-free survival when given as maintenance therapy to patients extensive stage small cell lung cancer, according to the latest findings from the IMpower 133 trial.
Read More
Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC
January 31st 2021Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.
Read More
ADC Datopomab Deruxtecan Shows Responses Across Doses in Advanced NSCLC
January 31st 2021Datopotamab deruxtecan showed antitumor activity in the treatment of patients with advanced or metastatic non–small cell lung cancer, according to updated results of the phase 1 TROPION-PanTumor01 trial.
Read More
Addition of Ipilimumab to Pembrolizumab Not Additive in Frontline PD-L1–High NSCLC
January 31st 2021Survival was not improved with the immunotherapy combination of pembrolizumab and ipilimumab in comparison with pembrolizumab monotherapy in the first-line treatment of patients with metastatic non–small cell lung cancer who had high PD-L1 expression and did not harbor EGFR or ALK aberrations, findings from the phase 3 KEYNOTE-598 trial showed.
Read More
Response and Resection Rates Following Neoadjuvant Atezolizumab Impress in Resectable NSCLC
January 30th 2021Neoadjuvant atezolizumab followed by surgery led to a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, according to findings from the primary analysis of the LCMC3 trial.
Read More
DFS Prolonged With Adjuvant Osimertinib Despite Prior Adjuvant Chemo in EGFR+ NSCLC
January 29th 2021In patients with EGFR-mutated non–small cell lung cancer, adjuvant treatment with osimertinib in the pivotal phase 3 ADAURA trial led to improvement in disease-free survival, irrespective of previous adjuvant chemotherapy received or disease stage.
Read More
Outcomes of Larotretinib Confirmed in TRK Fusion-Positive Lung Cancer
January 29th 2021Lyudmila A. Bazhenova, MD, explains the impact of having larotrectinib results in a lung cancer cohort, as seen in a presentation of data from 14 patients, given during the 2020 World Conference on Lung Cancer Singapore.
Read More
Encouraging Activity Shown With Trastuzumab Deruxtecan in HER2-Overexpressing NSCLC
January 29th 2021Antitumor activity was demonstrated with trastuzumab deruxtecan treatment in patients with HER2-overexpressing non–small cell lung cancer, regardless of HER2 expression levels, according to interim findings from a cohort of the phase 2 DESTINY Lung-01 trial.
Read More